Isoprostane as a Marker of Oxidative Stress in Chronic Heroin Users: Correlation with Duration of Heroin Use or Concomitant Hepatitis C Infection

REFERENCES

• Hayden MR, Whalley-Conell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: Paying homage to the podocyte. Am J Nephrol 2005; 25:553–569.
   PubMed Web of Science ®Google Scholar
• Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 1985; 117:793–795.
   PubMed Web of Science ®Google Scholar
• Zhou JF, Yan XF, Ruan ZR, Peng FY, Cai D, Yuan H. Heroin abuse and nitric oxide, oxidation, peroxidation, lipoperoxidation. Biomed Environ Sci 2000; 13:131–139.
   PubMed Web of Science ®Google Scholar
• Xu B, Wang Z, Li G, Li B, Lin H, Zheng R, Zheng Q. Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. Basic Clin Pharmacol Toxicol 2006; 99(2):153–161.
   PubMed Web of Science ®Google Scholar
• Pan J, Zhang Q, Zhang Y, Ouyang Z, Zheng Q, Zheng R. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 2005; 77(2):183–193.
   PubMed Web of Science ®Google Scholar
• Qiusheng Z, Yuntao Z, Rongliang Z, Dean G, Changling L. Effects of verbascoside and luteolin on oxidative damage in brain of heroin treated mice. Pharmazie 2005; 60(7):539–543.
   PubMed Web of Science ®Google Scholar
• Patel J, Manjappa N, Bhat R, Mehrotra P, Bhaskaran M, Singhal PC. Role of oxidative stress and heme oxygenase activity in morphine-induced glomerular epithelial cell growth. Am J Physiol Renal Physiol 2003; 285(5):861–869.
   Web of Science ®Google Scholar
• Kovacic P. Unifying mechanism for addiction and toxicity of abused drugs with application to dopamine and glutamate mediators: electron transfer and reactive oxygen species. Med Hypotheses 2005; 65(1):90–96.
   PubMedGoogle Scholar
• Kovacic P, Cooksy AL. Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med Hypotheses 2005; 64(2):357–366.
   PubMedGoogle Scholar
• Pereska Z, Dejanova B, Bozinovska C, Petkovska L. Prooxidative/antioxidative homeostasis in heroin addiction and detoxification. Bratisl Lek Listy 2007; 108(9):393–398.
   PubMed Web of Science ®Google Scholar
• Zhou J, Si P, Ruan Z, Ma S, Yan X, Sun L, Peng F, Yuan H, Cai D, Ding D, Xu S. Primary studies on heroin abuse and injury induced by oxidation and lipoperoxidation. Chin Med J (Engl) 2001; 114:297–302.
   PubMed Web of Science ®Google Scholar
• Tretjak Z, Knight J, Wilkins J, Setoda D, Voorhees R. Lipoperoxides in sebum of substance users and controls. Ann Clin Lab Sci 1992; 22:214–220.
   PubMed Web of Science ®Google Scholar
• Evangelou A, Kalfakakou V, Georgakas P, Koutras V, Vezyraki P, Iliopoulou L, Vadalouka A. Ascorbic acid (vitamin C) effects on withdrawal syndrome of heroin abusers. In Vivo 2000; 14(2):363–366.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2—like compounds are produced in vivo in humans by a non-cycloxygenase, free-radical catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87(23):9383–9387.
   PubMed Web of Science ®Google Scholar
• Roberts L, Morrow J. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345:121–135.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Harris TM, Roberts LJ. Noncyclo-oxygenase oxidative formation of a series of novel prostaglandins. Analytical ramifications for measurement of eicosanoids. Anal Biochem 1990; 184:1–10.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Minton TA, Roberts LJ. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992; 44:155–163.
   PubMedGoogle Scholar
• Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: Markers and mediators of oxidative stress. FASEB Journal 2004; 18:1791–1800.
   PubMed Web of Science ®Google Scholar
• Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999; 459:259–262.
   PubMed Web of Science ®Google Scholar
• Gopaul NK, Halliwell B, Anggard EE. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radic Res 2000; 33:115–127.
   PubMed Web of Science ®Google Scholar
• Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25:279–286.
   PubMed Web of Science ®Google Scholar
• Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. J Hepatol 2002; 36:805–811.
   PubMed Web of Science ®Google Scholar
• Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, Nakagawa N, Kojima Y, Watanabe S, Adachi Y, Kaito M. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 2006; 21(12):1821–1825.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Iwasa M, Urawa N, Tanaka H, Fujita N, Kobayashi Y, Adachi Y, Kaito M. Elevation of 8-isoprostane in patients with hepatitis C virus infection undergoing hemodialysis. J Clin Virol 2006; 37(3):231–232.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; Washington, DC: American Psychiatric Association, 1994.
   Google Scholar
• McLellan A, Luborsky L, Cacciola J, Griffith J, Evans F, Barr H, O’Brien C. New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis 1985; 173:412–423.
   PubMed Web of Science ®Google Scholar
• Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 2008; 28(3):397–404.
   PubMed Web of Science ®Google Scholar
• Arana C, Cutando A, Ferrera MJ, Gómez-Moreno G, Worf CV, Bolaños MJ, Escames G, Acuña-Castroviejo D. Parameters of oxidative stress in saliva from diabetic and parenteral drug addict patients. J Oral Pathol Med 2006; 35(9):554–559.
   PubMed Web of Science ®Google Scholar
• Irshad M, Khushboo I, Singh S. Hepatitis C virus (HCV): A review of immunological aspects. Int Rev Immunol 2008; 27:497–517.
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999; 9(1):133–146.
   PubMed Web of Science ®Google Scholar
• Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, Montine TJ. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 2004; 128(1–2):117–124.
   PubMed Web of Science ®Google Scholar
• Praticò D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48(5):809–812.
   PubMedGoogle Scholar
• Sharma HS, Sjöquist PO, Ali SF. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 2007; 13(18):1903–1923.
   PubMed Web of Science ®Google Scholar
• Goudas LC, Langlade A, Serrie A, Matson W, Milbury P, Thurel C, Sandouk P, Carr DB. Acute decreases in cerebrospinal fluid glutathione levels after intracerebroventricular morphine for cancer pain. Anesth Analg 1999; 89(5):1209–1215.
   PubMed Web of Science ®Google Scholar